Back to results
US 2006/0234347 A1Published application
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
OwnerThomas Harding, Minh Nguyeninventors
Life of this patent
Estimating the term…
Abstract
Multivalent soluble receptor proteins that bind to more than one angiogenic factor are described. Nucleotide and vector sequences which encode the multivalent soluble receptor protein, as well as host cells which comprise them and methods of making and using them are also described. The multivalent soluble receptor proteins and vectors which encode them find utility in treatment of cancer and other diseases associated with angiogenesis.
Claims42
A nucleotide sequence encoding a multivalent soluble receptor protein comprising:
- (a) the coding sequence for at least two domains selected from the group consisting of a PDGFR-alpha Ig-like domain, a PDGFR-beta Ig-like domain, a Fibroblast Growth Factor Receptor 1 (FGFR1) Ig-like domain, a Fibroblast Growth Factor Receptor 2 (FGFR2) Ig-like domain, a Hepatocyte Growth Factor Receptor (HGFR) SEMA domain-like domain;
- and
- (b) the coding sequence for a heterologous multimerizing domain.
A nucleotide sequence encoding a multivalent soluble receptor protein comprising,
- (a) the coding sequence for a Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Ig-like domain 2 and a Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Ig-like domain 3;
- (b) the coding sequence for at least two additional domains selected from the group consisting of a PDGFR-alpha Ig-like domain, a PDGFR-beta Ig-like domain, a Fibroblast Growth Factor Receptor 1 (FGFR1) Ig-like domain, a Fibroblast Growth Factor Receptor 2 (FGFR2) Ig-like domain, a Hepatocyte Growth Factor Receptor (HGFR) SEMA domain;
- and
- (c) the coding sequence for a multimerizing domain.
1 more element
Dependencies are inferred from the claim text.